Glycemic profile and lipid profile in COPD patients with and without Metabolic syndrome.

You must change your perspective in order to have a deeper comprehension of the connection between metabolic syndrome (MetS) and chronic obstructive pulmonary disease (COPD). This means using a patient management approach that is more system- and holistic-focused. This change recognizes the reality that the human body is a complex network of interrelated organs and systems and that illness in one area of the body may spread to seemingly unrelated areas of the body. Aim: The purpose of this study is to determine the lipid profile, mean blood glucose while fasting, impaired fasting glucose, and COPD patients with and without MetS. Materials & methods: After receiving permission from the Institutional Ethics Committee, the researchers started to work on their project. Patients diagnosed with MetS/COPD numbered a total of one hundred. We obtained information on the patient's whole medical history, including details about their occupation, income, smoking habits, diabetes, hypertension, and acute episodes. When determining body composition, height and mass were also taken into consideration. Every patient had a chest x-ray as well as an electrocardiogram. Result: The study indicated that fifty-five percent of patients had abdominal obesity, fifty-two percent had hypertension, fifty-two percent had impaired fasting glucose, forty-two percent had elevated triglycerides, and forty-eight percent had inadequate HDL cholesterol. We found hypertension, diabetes, and dyslipidemia to be the most frequent factors, contrary to global research that found abdominal obesity to be the most common. Our department must enhance non-communicable disease screening to detect COPD patients with undiagnosed diabetes, dyslipidemia, or hypertension. Conclusion: Abdominal obesity, high blood pressure, high triglycerides, and low HDL cholesterol were more common in metabolic syndrome patients. Many differences existed between the groups. Patients with COPD who also have diabetes, impaired fasting glucose, dyslipidemia, or high blood pressure should begin adequate antihypertensive medicine, oral hypoglycemic drugs or insulin, and lipid-lowering therapy. Patients with COPD who only have one of these conditions should begin all four therapies. Patients diagnosed with MetS had significantly higher levels of body mass index (BMI), weight, waist-hip ratio, hip circumference, and VLDL cholesterol. [ABSTRACT FROM AUTHOR]